|
21 Dec 2018 |
Independent Data Monitoring Committee Recommends Discontinuation of the Phase 2b STRIVE Clinical Trial of Staphylococcus aureus Vaccine Following Planned Interim Analysis
|
|
20 Dec 2018 |
Aimmune Therapeutics Announces IND Filing for AR201 for Egg Allergy and Exclusive Supply Agreement with Michael Foods
|
|
20 Dec 2018 |
HOOKIPA Doses First Patient in a Phase 2 Clinical Trial of Prophylactic Vaccine Candidate HB-101 against Cytomegalovirus
|
|
20 Dec 2018 |
Aimmune Therapeutics Initiates Phase 3 POSEIDON Trial for Treatment of Peanut Allergy in 1–3-Year-Old Children
|
|
20 Dec 2018 |
ILiAD Biotechnologies Secures Up to $20 million of Financing and Phase 2a BPZE1 Pertussis Vaccine Trial Initiates at Vanderbilt University Medical Center
|
|
19 Dec 2018 |
Dengvaxia® vaccine approved for prevention of dengue in Europe
|
|
17 Dec 2018 |
Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate
|
|
15 Dec 2018 |
VAXIMM Initiates Phase I/II Trial with VXM01 Oral T-cell Immunotherapy in Combination with PD-L1 Inhibitor Avelumab in Glioblastoma
|
|
15 Dec 2018 |
Anergis Reports Positive Preclinical Proof-of Concept Data of the Second-Generation COP Allergy Vaccine
|
|
14 Dec 2018 |
Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
|
|
06 Dec 2018 |
Neon Therapeutics and Apexigen Announce First Patient Dosed in Neon’s NT-003 Phase 1b Combination Trial of NEO-PV-01 in Metastatic Melanoma
|
|
04 Dec 2018 |
Phase 2 cancer study will evaluate T cell-activating immunotherapy MEDI0457 with MedImmune’s durvalumab targeting several HPV-related cancers
|
|
03 Dec 2018 |
Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of G100 and Pembrolizumab
|
|
28 Nov 2018 |
Generex Biotechnology Signs Clinical Trial Agreement With the NSABP Foundation, Inc. for Phase II Clinical Trial of AE37 in Combination With Pembrolizumab (Keytruda®) for Treatment of Triple-Negative Breast Cancer
|
|
26 Nov 2018 |
SELLAS Life Sciences Announces Completion of Enrollment in Phase 2 Randomized Controlled Clinical Study of Nelipepimut-S Plus Trastuzumab in High-risk, High-expression HER2 Breast Cancer Patients
|
|
20 Nov 2018 |
Stallergenes Greer Announces That the Phase III Trial for Its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved Its Primary Endpoint
|
|
20 Nov 2018 |
DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children
|
|
20 Nov 2018 |
Emergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus
|
|
14 Nov 2018 |
Merck Begins Rolling Submission of Licensure Application for V920 (rVSV∆G-ZEBOV-GP) to U.S. Food and Drug Administration
|
|
13 Nov 2018 |
Transgene - Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018
|
|
09 Nov 2018 |
Gradalis® Presents Initial Data from Phase II U.S. Trial for Ewing’s sarcoma at the Annual Meeting of the Children’s Oncology Group
|
|
08 Nov 2018 |
Neovacs announces in vivo Proof of Concept success for its IL-4 / IL-13 Kinoid a new Therapeutic Vaccine to treat Mite-induced Asthma
|
|
05 Nov 2018 |
Curevo Announces FDA Advancement of IND Application for CRV-101, New Shingles Vaccine Candidate
|
|
05 Nov 2018 |
Imcyse successfully completes patient enrollment in first-in-human Phase 1b study in type 1 diabetes
|
|
02 Nov 2018 |
Bavarian Nordic Announces Initiation of Clinical Trial Evaluating the Combination Therapy of CV301 and Durvalumab in Metastatic Colorectal and Pancreatic Cancers
|
